Patents by Inventor Shripad Venkatraman Bhagwat

Shripad Venkatraman Bhagwat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating cancer using a combination of SERD Dosing Regimens
    Publication number: 20220288019
    Abstract: Disclosed herein are dosing regimens for the administration of a compound of Formula I: or pharmaceutically acceptable salt thereof to patients in need of such treatment. The dosing regimens include adjuvant therapy.
    Type: Application
    Filed: March 8, 2022
    Publication date: September 15, 2022
    Inventors: Shripad Venkatraman BHAGWAT, Lillian Mary SMYTH, Suzanne Rebecca Lou YOUNG, Natalie Starr HOLMAN, Daniel Jon SALL, Safi SHAHDA, Eunice Soek Mun YUEN
  • TRIPLE COMBINATION OF AN ERK1/2 INHIBITOR WITH A BRAF INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF BRAFv6ooE COLORECTAL CANCER
    Publication number: 20220168250
    Abstract: The present invention relates to a combination of an ERK1/2 inhibitor, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof, with encorafenib, or a pharmaceutically acceptable salt thereof, and cetuximab and to methods of using these combinations to treat certain disorders, such as colorectal cancer.
    Type: Application
    Filed: May 12, 2020
    Publication date: June 2, 2022
    Inventors: Shripad Venkatraman BHAGWAT, Sajan JOSEPH, Ramon Velasquez TIU
  • ERK INHIBITORS
    Publication number: 20160375030
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 29, 2016
    Inventors: Shripad Venkatraman Bhagwat, Sajan Joseph
  • ERK inhibitors
    Patent number: 9526733
    Abstract: The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: December 27, 2016
    Assignee: Eli Lilly and Company
    Inventors: Shripad Venkatraman Bhagwat, Sajan Joseph